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Introduction
Type 2 diabetes (T2D) is reaching epidemic proportions
in Westernized countries owing to the intersection of
excess calorie consumption and reduced physical activ-
ity imposed on a genetically prone population. Nearly
one in 10 individuals in the US have diabetes and it is
projected that currently one in three newly born will
eventually develop diabetes (see http://www.cdc.gov/
chronicdisease/resources/publications/AAG/ddt.htm,
accessed 5 October 2011). Diabetes is diagnosed now in
younger people and there is much concerned specula-
tion as to how the health economic consequences of
diabetes may manifest over the upcoming decades.
Most newly diagnosed and established patients with
T2D are overweight or obese and current treatment
algorithms place emphasis on initial lifestyle modiﬁca-
tion entailing a low-calorie diet with regular exercise in
order to improve metabolic state and reduce body
weight.
1 Lifestyle modiﬁcation alone has a low likeli-
hood of sustained metabolic improvement and T2D is
a progressive disease, likely through the inexorable
decline in b-cell function, and for this reason there is
an increasing need for pharmacological intervention
over time. The diabetes armamentarium has well-estab-
lished therapies, each of the more historic mainstays
(insulin, metformin and sulfonylureas) having accumu-
lated between 60 and 90 years of clinical experience,
and a number of additional oral agent classes intro-
duced over the past 15 years.
In general, if glycemic goals (HbA1c <7) are not
achieved or sustained with lifestyle modiﬁcation,
metformin is strongly positioned as ﬁrst-line oral ther-
apy, largely because of long experience in the clinic,
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Abstract
Incretin-based therapies have established a foothold in the diabetes arma-
mentarium through the introduction of oral dipeptidyl peptidase-4 inhibi-
tors and the injectable class, the glucagon-like peptide-1 receptor agonists.
In 2009, the American Diabetes Association and European Association for
the Study of Diabetes authored a revised consensus algorithm for the initi-
ation and adjustment of therapy in Type 2 diabetes (T2D). The revised
algorithm accounts for the entry of incretin-based therapies into common
clinical practice, especially where control of body weight and hypoglycemia
are concerns. The gut-borne incretin hormones have powerful effects on
glucose homeostasis, particularly in the postprandial period, when approxi-
mately two-thirds of the b-cell response to a given meal is due to the incre-
tin effect. There is also evidence that the incretin effect is attenuated in
patients with T2D, whereby the b-cell becomes less responsive to incre-
tin signals. The foundation of incretin-based therapies is to target this
previously unrecognized feature of diabetes pathophysiology, resulting in
sustained improvements in glycemic control and improved body weight
control. In addition, emerging evidence suggests that incretin-based thera-
pies may have a positive impact on inﬂammation, cardiovascular and hepa-
tic health, sleep, and the central nervous system. In the present article, we
discuss the attributes of current and near-future incretin-based therapies.
Keywords: glucagon-like peptide-1, incretins, pathophysiology, Type 2
diabetes.
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safety and tolerability proﬁles, neutral effects on body
weight, and low cost. Then, in a stepwise manner, fur-
ther oral agents are added with the eventual need for
insulin, ﬁrst in the basal long-acting form and then
later the use of more intensiﬁed insulin regimens.
Despite this array of oral agents and advances in insu-
lin delivery, pharmacological intervention often falls
short of treatment goals with the price of unwanted
side effects, namely weight gain and hypoglycemia.
Incretin-based therapies were developed after the
observation during the 1960s of an incretin signal origi-
nating from the gut that augmented the b-cell response
to caloric intake
2 and the later discovery that the gut
hormones glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) play a cen-
tral role in this physiological response.
3–7 It is evident
that this physiological response is mostly relevant in the
postprandial period; however, rodent data have also
shown that GLP-1 may play a tonic role in regulating
fasting plasma glucose. The incretin response is thought
to be defective in T2D, manifesting in part with a com-
plete lack of b-cell responsiveness to exogenously
administered GIP.
6,8 The b-cell maintains responsive-
ness to exogenously administered GLP-1, but the
response may be somewhat attenuated compared with
that seen in the non-diabetic state, indicating a partial
incretin defect with GLP-1.
9 Due to these effects on
the b-cell, GLP-1 became an attractive pharmacologic
target, and harnessing it in some fashion was enticing. This
had to be accomplished while overcoming a key short-
coming of the native GLP-1 peptide, namely its suscep-
tibility to rapid breakdown by the ubiquitous protease
dipeptidyl peptidase-4 (DPP-4), rendering the native
hormone incapable of a useful pharmacologic effect
unless infused continuously. Over the past 5 years, we
have seen the emergence of the DPP-4 inhibitor oral
agent class and the injectable GLP-1 receptor agonist
class. Both pharmaceutical preparations have overcome
the instability of native GLP-1 and have been important
new additions, with well-documented beneﬁcial effects
on glycemic control and short-term effects on b-cell
function. However, to date, no long-term b-cell-preserv-
ing effects have been documented. Regardless, the wider
physiologic role of the incretin hormones has uncovered
a wide array of pharmacologic effects that may be of
particular advantage to patients with T2D.
Incretin-based therapies: Leveraging the effects
of GLP-1
Much of the initial focus of GLP-1 has been its effect
on the b-cell. It is known that GLP-1 enhances insulin
secretion in a glucose-dependent manner, meaning that
insulin secretion is most demonstrable when plasma
glucose is abnormally elevated and not seen when
plasma glucose is below the normoglycemic range,
thereby resulting in low risk of hypoglycemia.
10 The
effect on the b-cell is immediate and robust, namely
restoration of ﬁrst-phase insulin secretion,
10 a well-
characterized defect seen early in T2D and not cor-
rected by other pharmacological interventions. This
response, an artiﬁce of an experimental challenge to
the b-cell, gains clinical relevance when a similar early
robust response of the b-cell to a meal challenge results
in a powerful effect, namely the prevention of an
abnormal rise in postprandial plasma glucose. In addi-
tion, GLP-1 slows gastric emptying and reduces the
secretion of glucagon in a glucose-dependent manner,
both of which further contribute to the reduction of
elevated postprandial plasma glucose.
10 The effects of
GLP-1 are not conﬁned to the postprandial state,
because clinical data demonstrate a lowering of abnor-
mally elevated fasting plasma glucose to the normal
range when the hormone is infused intravenously; this
appears to be b-cell mediated, because insulin secretion
increases concomitantly.
10 The effects of GLP-1 on the
b-cell are not conﬁned to a glucose-dependent stimula-
tion of insulin secretion; favorable effects on upstream
insulin biosynthesis are also observed
11 and, over the
longer-term, an effect to potentially restore b-cell func-
tion and mass has been observed in preclinical mod-
els.
12–14 This preclinical ﬁnding has raised speculation
concerning the potential for a truly disease-modifying
impact of GLP-1 pharmacology on T2D and also pos-
sibly on Type 1 diabetes.
The wider array of glucoregulatory effects of GLP-1
can be described as b-cell sparing because they reduce
the workload of the b-cell by: (i) suppressing the cata-
bolic hormone glucagon, which is abnormally elevated
in the diabetic setting, particularly postprandially;
(ii) slowing of gastric emptying postprandially, thereby
allowing a more timely delivery of nutrients into the
portal and then systemic circulation; (iii) suppressing
appetite, reducing food intake and therefore the calo-
ric load required to be assimilated in fuel stores;
(iv) reducing body weight, likely a consequence of effects
on satiety; (v) insulin-sensitizing effects, clearly seen in
animal models
15 but somewhat disputed in humans
and, if observed, often considered to be a secondary
response to weight loss; (vi) an insulin-independent
effect on glucose clearance from the circulation that
may be mediated through portal signaling (Table 1).
15
Beneﬁcial effects are also seen in the cardiovascular
system, including protective actions in the cardio-
myocyte at a molecular level and improved cardiac
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inﬂammatory, cardiorenal, and peripheral vasodilatory
effects have been reported.
16–18 There is also a body of
work that highlights the potential downstream cardiac
effects of the DPP-4-cleaved GLP-1 metabolic product
GLP-1(9-36).
18 It is unclear as yet whether GLP-
1(9-36) serves an important physiologic role, how its
actions are elicited at the receptor level, and how this
cleaved product may inﬂuence what we observe with
GLP-1-based pharmacology. In summary, GLP-1
pharmacology may have potential cardiovascular bene-
ﬁts for patients with T2D and has the potential to
exert speciﬁc cardiac beneﬁt in certain acute care
settings. That said, there is currently only a limited
body of supporting evidence from the clinic.
Glucagon-like peptide-1 (GLP-1) has been an attrac-
tive pharmacologic target for some time and it has
now been harnessed in two very different forms: the
DPP-4 inhibitor class and the GLP-1 receptor agonists.
The former is represented by the introduction of three
oral agents in the US and a fourth available in Eur-
ope. The GLP-1 receptor agonist class ﬁrst emerged as
the twice a day injectable exenatide and, since then,
efforts have been directed at leveraging GLP-1 actions
in a less frequent dosing platform.
Glucagon-like peptide-1 receptor agonists:
Clinical review
Exenatide (exendin-4) was the ﬁrst available GLP-1
receptor agonist and was originally isolated from the
salivary secretion of the Gila monster.
19 Exenatide has
approximately 50% amino acid sequence identity to
GLP-1, with which it shares many glucoregulatory
effects. However, unlike GLP-1, exenatide is resistant
to DPP-4 degradation, which gives it a half-life of
2.4 h in the circulation, making it amenable to twice-
daily injectable subcutaneous administration.
20
Early mechanistic work with the exenatide molecule
established many of the attributes already seen with
GLP-1: glucose-dependent actions on both b- and
a-cells,
21 restoration of ﬁrst- and second-phase insulin
secretion,
21 slowing of gastric emptying,
22 satiety
effects at mealtime,
23 and powerful glucose lowering in
both the fasting and postprandial states (Table 1).
22 In
the original major long-term clinical trials with exena-
tide as an adjunct to oral agents, 10 lg exenatide twice
daily (b.i.d.) reduced HbA1c (approximately 1%) and
body weight (approximately 3 kg) in patients with
T2D.
24–27 This was a unique moment in the treatment
of T2D because although historic interventions elicited
glycemic improvement, this was invariably coupled
with weight gain or, at best, weight neutrality. Trial
extension data out to 3 years with the completer popu-
lation showed exenatide elicited sustained reductions in
HbA1c (approximately 1%) and body weight (approxi-
mately 5 kg).
28
The efﬁcacy of exenatide has also been compared
with basal and biphasic insulin regimens in patients
with T2D.
29–32 Comparing 10 lg exenatide b.i.d. with
optimally titrated insulin glargine in trials of up to
52 weeks duration,
29,30,32 and a further study compar-
ing 10 lg exenatide b.i.d. or insulin lispro 70⁄30 for
52 weeks,
31 revealed equivalent reductions in HbA1c
between exenatide and insulin in the range of 0.8–
1.4%.
29–32 However, the means by which overall glyce-
mic improvements were achieved differed between the
two interventions: insulin treatment had a greater low-
ering effect on fasting plasma glucose, whereas a
greater reduction in postprandial glucose excursion
Table 1 Glucoregulatory effects of glucagon-like peptide-1 (GLP-1) and incretin-based therapies
GLP-1 GLP-1 receptor agonists DPP-4 inhibitors
Enhanced glucose-dependent
insulin secretion
Yes Yes, including restoration
of ﬁrst-phase insulin
response to i.v. glucose
Yes
Suppression of inappropriately
elevated glucagon secretion
Yes Yes Yes
Regulation of gastric emptying Yes Yes No
Suppression of appetite Yes Yes No
Weight reduction Yes Yes No: neutral effects
on weight
Improved b-cell function Yes* Yes Yes
*Glucagon-like peptide-1 (GLP-1) exerts trophic effects on primary islet cultures, in vivo b-cell models, and b-cell lines, promoting b-cell prolif-
eration and neogenesis while reducing b-cell apoptosis.
110–113 In addition, GLP-1 also promotes differentiation of non-insulin cells into cells
able to secrete insulin.
114
DPP-4, Dipeptidyl peptidase-4.
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29–32 Also of note, exena-
tide reduced body weight in all studies compared with
the weight gain seen with insulin treatment.
29–32
A long-acting, sustained-release formulation of
exenatide is currently in development for use as a
once-weekly injection.
33 This technology consists of
unaltered exenatide encased within a biodegradable
medical polymer, namely poly(d,l-lactic-co-glycolic
acid), that allows gradual, controlled drug delivery
over an extended period of time.
34 Early clinical work
has shown that the once-weekly platform elicits a
greater effect on fasting plasma glucose and HbA1c
(approximately 1.7% lowering) than that seen with
exenatide b.i.d., but similar effects on body weight.
33
In subsequent longer-term clinical trial work, 2 mg
exenatide once weekly has consistently resulted in
HbA1c lowering in the 1.5–2.0% range, with weight
effects similar to those seen with exenatide b.i.d. Studies
have compared exenatide once weekly with exenatide
b.i.d., maximal dosing of either pioglitazone or
sitagliptin, and optimally titrated glargine insulin.
35–37
In each study, exenatide once weekly has established
superiority with regard to lowering HbA1c, coupled
with reproducible weight reduction. Exenatide once
weekly is currently under review with the US Food
and Drug Administration (FDA).
Liraglutide is a modiﬁed analog of human GLP-1,
with an arginine to lysine amino acid substitution
(position 34) and the attachment of a glutamic acid
residue with palmitic acid (C-16 fatty acid) to an exist-
ing lysine residue (position 26). These modiﬁcations
render liraglutide 97% homologous to human GLP-1,
resistant to DPP-4 cleavage and with an increased
half-life of 13 h in the circulation, making it suitable
for once-daily administration by subcutaneous injec-
tion.
38 In clinical trials, the maximally recommended
dose of liraglutide (1.8 mg) reduced HbA1c by 1.0–
1.5% and body weight by approximately 2 kg in dif-
ferent trials in which it was compared with metformin,
glimepiride, rosiglitazone, or insulin glargine.
39–43 Of
note, liraglutide was also compared with exenatide
b.i.d. in a recent 26-week trial and was found to have
a signiﬁcant advantage over exenatide b.i.d. in terms
of HbA1c lowering, but equivalent effects on body
weight.
44 Liraglutide was recently approved as a once
a day GLP-1 agonist at doses of 0.6–1.8 mg⁄day.
44
In addition to exenatide b.i.d., exenatide once
weekly, and liraglutide, an array of additional GLP-1
receptor agonists are in earlier stages of clinical devel-
opment.
45–51 Taspoglutide is a highly modiﬁed analog
of human GLP-1 (93% homology) with two aminoiso-
butyric acid substitutions at positions 8 and 35 and a
sustained-release formulation, which makes it resistant
to degradation by DDP-4 and potentially suitable for
once weekly administration.
45 However, the develop-
ment of taspoglutide has recently been suspended
owing to serious hypersensitivity reactions and gastro-
intestinal side effects reported in clinical trials. Albi-
glutide is a GLP-1 genetic dimer fused to human
albumin, which confers resistance to DPP-4, making
this agent potentially suitable for once weekly adminis-
tration.
46–48 Lixisenatide (AVE-0010) is a modiﬁed exe-
natide molecule with six C-terminal lysine residues,
which confers resistance to degradation by DPP-4 and
favors once or twice daily administration.
49–51
Dipeptidyl peptidase-4 inhibitors: Clinical review
Dipeptidyl peptidase-4 inhibitors differ greatly from the
GLP-1 receptor agonists in that they are small mole-
cules, rather than peptides, and thus can be adminis-
tered orally rather than by subcutaneous injection. They
inhibit the action of DPP-4 to cleave GLP-1 to its inac-
tive form and therefore elevate levels of native GLP-1 in
the circulation. Dipeptidyl peptidase-4 is a ubiquitous
enzyme in the circulation, where, in addition to GLP-1,
it cleaves other peptides, such as native GIP; it is
inferred that the glucose-lowering effects of this class of
drugs are through actions on GLP-1, but perturbation
of other peptide systems cannot be excluded.
52
There are nuances in the pharmacologic charac-
teristics of the drugs within the class (e.g. the ﬁrst com-
mercially available DPP-4 inhibitor, sitagliptin, binds
non-covalently to the enzyme, whereas vildagliptin and
saxagliptin bind covalently to DPP-4), which provide
each agent with unique reversible binding properties and
potential fordifferences in their pharmacologic action.
The clinical efﬁcacy of the DPP-4 inhibitors is mod-
est compared with that seen with the GLP-1 receptor
agonists (Table 1). In long-term clinical trials, sitaglip-
tin reduced HbA1c in the region of 0.6–0.7%, with a
modest reduction in fasting plasma glucose.
53–59 Trials
of sitagliptin also demonstrated weight neutrality.
53–59
These ﬁndings have been reproduced in clinical work
with vildagliptin and saxagliptin, and there is evidence
that earlier-stage DPP-4 inhibitors in development also
have similar effects.
60–66
Comparison of GLP-1 receptor agonists and
DPP-4 inhibitors
Several recent trials have directly compared incretin-
based therapies, to some degree addressing questions
concerning relative efﬁcacy and safety of short-
versus long-acting GLP-1 receptor agonists and DPP-4
inhibitors.
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pared in two 2-week cross-over trials.
23,67 Compared
with sitagliptin, exenatide improved 2-h postprandial
glucose and insulin secretion, reduced the abnormal
rise in postprandial glucagon secretion, reduced plasma
triglycerides, slowed gastric emptying, and reduced
caloric intake.
In another study, exenatide once weekly was com-
pared with sitagliptin over a period of 26 weeks.
36 Exe-
natide once weekly reduced HbA1c and body weight
by 1.5% and 2.3 kg, respectively, compared with
decreases of 0.9% and 1.5 kg, respectively, seen with
sitagliptin.
36 Exenatide once weekly also improved sys-
tolic blood pressure, the albumin:creatinine ratio, and
B-type natriuretic peptide compared with sitaglitpin,
which had no signiﬁcant effect on these parameters.
36
Once-daily liraglutide was compared with sitagliptin
in another 26-week study.
68 Liraglutide reduced
HbA1c and body weight by 1.5% and 3.4 kg, respec-
tively, compared with decreases of 0.9% and 1.0 kg,
respectively, seen with sitagliptin. Liraglutide also
improved fasting plasma glucose (but not postprandial
glucose), HOMA-B, C-peptide concentrations, the pro-
insulin:insulin ratio, and total cholesterol compared
with sitagliptin.
68
On balance, in head-to-head to studies, the GLP-1
receptor agonist class has demonstrated a more potent
glycemic-lowering effect than the DPP-4 inhibitors,
coupled with weight loss rather than weight neutrality.
Mechanistically, it would appear the islet actions and
effects on gastric emptying are more potent with the
pharmacologic concentrations achieved with the inject-
able therapies, coupled with effects on satiety and food
intake, which likely contribute to the weight loss
observed.
Safety and tolerability of incretin-based therapies
The introduction of new therapeutic approaches and
new pharmaceutical entities requires an appropriate
assessment of safety as well as efﬁcacy. The safety pro-
ﬁle of GLP-1 receptor agonists seems fairly consistent
across different platforms, with some exceptions. First
and foremost, the most common issues reported with
incretin-based therapies are tolerability issues. Nausea
is the most commonly reported event, and tends to be
a short-lived phenomenon in the early days or weeks
of therapy, but there is a minority of patients who
have more severe symptoms and will not tolerate ther-
apy. Other gastrointestinal side effects (e.g. diarrhea)
are seen less commonly. Among the more established
programs, exenatide once weekly has an improved tol-
erability proﬁle than exenatide b.i.d. and liraglutide
seems similar to exenatide b.i.d., although the overall
rate of nausea is reported to be greater with exenatide
b.i.d.
35,44 Both liraglutide and exenatide b.i.d. require
titration steps to mitigate nausea (two steps for liraglu-
tide, one for exenatide b.i.d., compared with none for
exenatide once weekly). The DPP-4 inhibitors, unlike
the GLP-1 receptor agonists, are well tolerated with
respect to gastrointestinal side effects in most patients.
The risk of hypoglycemia is an important consider-
ation for diabetes therapeutics. Because of the very
nature of the glucose dependency of the actions of
GLP-1 on b- and a-cells, hypoglycemia should be an
uncommon event. Mechanistically, this was demon-
strated in an elegant stepped hypoglycemic clamp set-
ting during a concomitant infusion of exenatide, where
the stimulatory actions on b-cells and suppressing
actions on a-cells were over-ridden promptly once
plasma glucose dropped below 90 mg⁄dL,
21 thus
allowing the primary counter-regulatory responses to
hypoglycemia (i.e. suppression of insulin secretion
from b-cells and a robust glucagon release from
a-cells) to occur unabated. These ﬁndings were reaf-
ﬁrmed in the clinic in an early Phase 3 trial in which
exenatide b.i.d. was added on a background metformin
therapy, with no increase in hypoglycemia despite a
reduction in HbA1c of approximately 1%.
25 The lack
of an increased risk of hypoglycemia in such a clinical
setting has been reproduced with both the longer-act-
ing form of exenatide and liraglutide and is a clear dif-
ferentiating feature of this injectable therapy, especially
when compared with its injectable counterpart, insu-
lin.
35–37,39–44 However, it should be noted that the
addition of GLP-1 receptor agonists to background
sulfonylurea therapy increases the risk of hypoglyce-
mia, necessitating titration of concomitant sulfonylurea
dosing, although severe hypoglycemic events are extre-
mely uncommon.
24 The DPP-4 inhibitors have no evi-
dence of increasing the risk of hypoglycemia, much
like the peroxisome proliferator-activated receptor c
agonists and metformin, and unlike the b-cell secreta-
gogue agents, the sulfonylureas and the meglinitides.
More serious but less common safety issues have
been highlighted that pertain to the pancreas, kidney,
thyroid C-cells, and immunogenicity. Pancreatitis ﬁrst
emerged as a potential safety consideration with the
ﬁrst GLP-1 receptor agonist exenatide b.i.d. and then
subsequently the ﬁrst DPP-4 inhibitor sitagliptin. Pan-
creatitis was not noted during the original regulatory
clinical trial work conducted prior to approval for
either compound, but instead during post-marketing
safety surveillance, when both therapies had been
prescribed in a much larger population. In order to
understand the signiﬁcance of these phenomena, a
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keting safety surveillance is key, namely an imprecise
numerator (i.e. reporter bias, data quality of safety
events and confounders) and denominator (i.e. difﬁ-
culty in capturing overall population drug exposure).
It was speculated that pancreatitis may be a condition
seen more often in the T2D population (irrespective of
treatment) and this has been conﬁrmed by an indepen-
dent epidemiological assessment, showing that patients
with diabetes have a near threefold increased risk of
pancreatitis compared with those without diabetes.
69
Associated epidemiological data have also reported no
increased risk of pancreatitis when one examines
patients initiated on either sitagliptin, exenatide b.i.d.,
insulin, or metformin.
70,71 Studies in animal models
have also tried to shed light on this safety issue with
mixed ﬁndings across a variety of models. Although it
is too early to examine the post-marketing experience
of liraglutide, a small number of cases of pancreatitis
were reported during clinical development; conse-
quently, liraglutide has a similar pancreatitis warning
to that seen with exenatide.
72
In addition, clinically relevant doses of liraglutide
and exenatide once weekly and toxicological doses of
exenatide b.i.d. have been reported to cause thyroid
C-cell adenomas and⁄or carcinomas in rodents during
2-year carcinogenicity studies (with unknown relevance
in humans). Data from limited studies suggest that the
human and rodent thyroid may respond differently to
GLP-1 because human thyroid cells seem to lack or
have low levels of GLP-1 receptors,
73,74 but additional
data are needed. As a result of thyroid safety concerns,
liraglutide received regulatory approval as an adjunct
to diet and exercise, but not as a ﬁrst-line agent.
72,75
The implications of these safety concerns as they relate
to other GLP-1 receptor agonist-based therapies are
currently unknown. In clinical studies, there have been
no reported cases of thyroid cancer during treatment
with liraglutide,
39–44 exenatide b.i.d.,
24–27 or exenatide
once weekly.
35–37 However, further preclinical studies
and a 15-year cancer registry for liraglutide have been
initiated.
75
In general, DPP-4 inhibitors have a relatively clear
safety record, with lower reported rates of adverse
events than GLP-1 receptor agonists. The incidence of
hypoglycemia with DPP-4 inhibitors has been low, but
is higher in patients also using sulfonylurea.
76
Potential safety concerns with DPP-4 inhibitors
include post-marketing reports of hypersensitivity
reactions, including anaphylaxis, angioedema, rash,
urticaria, and exfoliative skin conditions such as
Stevens–Johnson syndrome.
76 It is speculated that
these conditions may result from the blockade of GIP
degradation, as well as that of other peptides, such as
the glucagon secretin family hormones, pancreatic
polypeptide proteins, neuropeptides, and chemokines.
Moreover, membrane-bound DPP-4, originally identi-
ﬁed as CD26, is involved in immune system function
and plays a role in cell signaling, the regulation of
extracellular matrix binding, and ion transport.
77
Incretin-based therapies: Beyond glycemic
control
Incretin-based therapies represent an important step
forward in the treatment of T2D, addressing, at least
in part, a previously neglected aspect of diabetes path-
ophysiology, namely the incretin defect. Incretin-based
therapies demonstrate a capacity to sustain long-term
improvements in glycemic control and, with GLP-1
receptor agonists, signiﬁcant reductions in body
weight. Moreover, incretin-based therapies have the
potential for disease modiﬁcation by eliciting funda-
mental improvements in b-cell function, primarily
noted with the GLP-1 receptor agonist class.
30,78
Emerging data, primarily with GLP-1 receptor agon-
ists, again also reports the improvement of several key
cardiovascular risk factors, including lipid proﬁles and
blood pressure. In clinical trials, exenatide b.i.d. treat-
ment was associated with signiﬁcant improvements
in lipid proﬁles, including high-density lipoprotein–
cholesterol (HDL-C), triglycerides, and total choles-
terol in patients who were treated for more than
3 years in open-label extension studies.
28 Data from
the liraglutide clinical development program also
reported signiﬁcant improvements in total cholesterol,
low-density lipoprotein–cholesterol (LDL-C), and
triglycerides.
39–44 Moreover, HDL-C, LDL-C, triglyce-
rides, and total cholesterol were reported to improve with
up to 2 years of treatment with exenatide once weekly.
79–81
In addition, effects on diastolic and systolic blood
pressure have been observed during the exenatide
b.i.d., liraglutide, and once-weekly development pro-
grams.
79–82 A recent pooled analysis of six exenatide
b.i.d. clinical trials of ‡26 weeks duration demon-
strated signiﬁcant reductions in systolic blood pressure
with exenatide compared with placebo or insulin.
82
Similarly, a pooled analysis of patients participating in
two exenatide once weekly trials for 52 weeks also
demonstrated signiﬁcant improvements in systolic
blood pressure compared with sitagliptin and pioglitaz-
one.
80 A meta-analysis from six 26-week trials during
liraglutide clinical development reported improved
endpoint systolic blood pressure.
83 It is signiﬁcant that
improvements in cardiovascular risk have been
reported to occur prior to, or be weakly correlated
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from exenatide b.i.d. and once weekly, as well as the
liraglutide clinical development programs, suggesting
direct effects of GLP-1 receptor agonists on blood
pressure.
79–83
Although the impact of these improvements in
cardiovascular risk factors on eventual events has not
yet been demonstrated directly, the cardiovascular risk
proﬁle associated with exenatide b.i.d. treatment has
been assessed in a meta-analysis of 12 clinical trials of
£52 weeks duration. Compared with a pooled com-
parator group, the relative cardiovascular event risk
associated with exenatide treatment was 0.80 [95%
conﬁdence interval (CI) 0.53–1.22].
84
Increasingly, liver fat content is being recognized as
another cardiovascular risk factor that often accompa-
nies T2D, because 80% of patients with diabetes are
thought to have concurrent fatty liver disease.
85 There
is early evidence that GLP-1 receptor agonists have
the potential to improve hepatic health,
28,79,80 as mea-
sured by hepatic enzyme concentrations, with implica-
tions for the treatment of non-alcoholic steatohepatitis
and non-alcoholic fatty liver disease, particularly in
patients with T2D. Up to 3.5 years of treatment with
exenatide b.i.d. or 1 year with exenatide once weekly
improved alanine transaminase (ALT) and aspartate
aminotransferase (AST), measures of hepatic function
that are commonly used surrogates of liver inﬂamma-
tion⁄steatosis.
28,79,80 Exenatide b.i.d. treatment has
also been demonstrated to reduce liver fat content in
individual patients. For example, a case study reported
that a male patient who had been treated with exena-
tide for 44 weeks experienced a reduction in liver fat
of 73% that was associated with improvements in liver
function (ALT – 26 IU⁄L and AST – 5 IU⁄L).
86 This
was accompanied by improvements in blood pressure,
LDL-C, HDL-C, triglycerides, and HOMA-IR,
86 con-
sistent with the emerging link between liver fat⁄liver
function and cardiovascular risk factors.
87
Because of the observed effects on cardiovascular
risk markers in patients with T2D and the demonstra-
tion of GLP-1 receptor localization to cardiac and vas-
cular tissues, several investigations have addressed the
question of potential direct effects of GLP-1 receptor
agonists on the cardiovascular system. Exenatide has
been reported to have cardioprotective effects, mea-
sured by preserved cardiac function and reduced
infarct size in animal models of ischemia–reperfusion
injury in pigs and rodents.
18,88,89 Liraglutide was
reported to have no cardioprotective effect in a similar
pig ischemia–reperfusion injury model,
90 but it did
improve survival in mice following induced myocardial
infarction, reducing the number of cardiac ruptures
and infarct size and improving cardiac output.
91 Both
exenatide and liraglutide have been reported to modu-
late the expression of cardioprotective genes and to
reduce activation of the apoptotic pathway enzyme
caspase-3 during ischemic insults.
88,91
Exenatide b.i.d. has been reported to reduce C-reac-
tive protein, a measure of inﬂammation,
92,93 total
adiponectin, and the oxidative stress marker malon-
dialdehyde compared with insulin glargine in studies of
£52 weeks duration.
93,94 In addition, 52 weeks of exe-
natide b.i.d. treatment reduced resistin and retinol
binding protein-4 (measures of insulin resistance), as
well as C-reactive protein concentrations, compared
with glibenclamide.
95
In comparison with GLP-1 receptor agonists, there
are signiﬁcantly less data available describing the
effects of DPP-4 inhibitors on cardiovascular risk. In
clinical trials, sitagliptin was reported to elevate HDL-
C, whereas vildagliptin was reported to lower choles-
terol and triglycerides.
58,66 A systematic assessment of
cardiovascular risk across eight randomized trials in
the saxagliptin clinical development program reported
no increased relative risk (RR 0.43; 95% CI 0.23–0.80)
of a compound endpoint (cardiovascular death, myo-
cardial infarct, and stroke) compared with placebo,
metformin, or glyburide.
96
Glucagon-like peptide-1 acts through a well-
described gut–central nervous system axis to exert cen-
tral effects on food intake and satiety. Glucagon-like
peptide-1 receptors are located in the brain and emerg-
ing evidence suggests that GLP-1 may have effects
beyond modulating food intake, including modulating
sleep patterns,
97 limiting inﬂammation,
98,99 and neuro-
protection.
100–102 It should be noted that this evidence
is from animal models and that no human data are
available; consequently, the potential beneﬁts to
humans are speculative in nature.
There is strong evidence to indicate that disrupted
sleep (reduced sleep duration and⁄or quality) leads to
reduced glucose tolerance, reduced insulin sensitivity,
and dysregulation of appetite.
103 Consequently, dis-
rupted sleep has been reported to be associated with
the increase in risk of developing T2D.
104,105 It has
been hypothesized that altered gut–brain satiety and
insulinotropic signaling may contribute, in part, to
these observed metabolic defects. In support of this,
preliminary evidence from animal models is consistent
with the existence of a link between GLP-1 receptor
signaling and circadian⁄sleep systems. The clock
mutant mouse, which is deﬁcient in a central circadian
regulator and displays disrupted circadian control, is
associated not only with symptoms of the meta-
bolic syndrome and diabetes, but also with increased
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of food intake and weight loss.
97 It is possible that
effects of exenatide on glucose tolerance and appetite
regulation could be associated with an improvement of
sleep duration and quality in patients with disordered
sleep, with or without diabetes.
Consistent with preclinical studies indicating that
exenatide may have protective and⁄or regenerative
effects on the b-cells in the pancreas, it appears GLP-1
receptor agonism may have similar effects in the brain.
Glucagon-like peptide-1 receptors are located in the
brain, where both GLP-1 and exenatide gain access via
the circumventricular organs. In addition, GLP-1
receptor-knockout mice display reduced synaptic plas-
ticity and disordered learning and memory, suggestive
of a role for GLP-1 receptors in normal neural func-
tion.
106 Glucagon-like peptide-1 receptor agonism has
been shown to have neurotrophic and neuroprotective
effects on neuronal cell types, including the promotion
of neurite outgrowth in cultured cells,
100,101 protection
of cultured neurons from apoptosis induced by trophic
factor deprivation,
102 oxidative insult, amyloid-b (Ab)
peptide exposure, and excitotoxic stimulation.
107 Fur-
thermore, in animal models of Alzheimer’s disease,
GLP-1 receptor agonism has been shown to reduce
levels of Ab peptide in the brain and reduce oxidative
damage.
108 In a mouse model of Parkinson’s disease
[1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)],
exendin-4 protected dopaminergic neurons against
MPTP-induced neurodegeneration, thereby preserving
dopamine levels and improving motor function.
109
Together, these ﬁndings, as well as a growing body of
additional data, provide the basis for speculation that
GLP-1 receptor agonism may have beneﬁcial effects
in patients with neurodegenerative diseases such as
Alzheimer’s disease and Parkinson’s disease.
The incretin-based therapies are currently labeled for
the treatment of patients with T2D. However, the
reported improvements in extraglycemic effects of
the class render incretin-based therapies, particularly
the longer-acting GLP-1 receptor agonists, as potential
candidates for the treatment of individuals at risk of
not just prediabetes and the metabolic syndrome,
where weight and cardiovascular outcomes are key
concerns, but also a number of additional disease
states, including sleep disorders and neurodegenerative
disease (Fig. 1).
Conclusions
The emergence of the ﬁrst incretin-based therapies,
exenatide and sitagliptin, has impacted the treatment
of T2D such that they have become important consid-
erations in the treatment armamentarium. These two
pioneer therapies are now followed by additional
DDP-4 inhibitor agents and GLP-1 receptor agonists
as the incretin-based therapies become increasingly
established. Both classes exhibit important glucose-
lowering effects and unique positive attributes. Drugs
in the DPP-4 inhibitor class are administered orally
and exhibit good tolerability and an acceptable safety
proﬁle, with the attraction of a low hypoglyce-
mic potential; in addition, they are weight neutral.
The GLP-1 receptor agonists are injectable, have
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Figure 1 Glucagon-like peptide-1 (GLP-1)
has established effects on glycemic control
and body weight, and is reported to have
positive impacts on cardiovascular risk,
inﬂammation, sleep, and hepatic health. In
addition, GLP-1 has been reported to have
neuroprotective, neurotrophic, and cardio-
protective effects. (See text for details).
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appear to have more glucose-lowering potential than
the DPP-4 inhibitors. They elicit signiﬁcant weight loss
in many patients and are associated with positive
effects on cardiovascular risk factors.
The GLP-1 receptor agonist class holds great
promise with the introduction of once-daily therapy
(liraglutide) and the possibility of once-weekly and
even once- monthly platforms in development. Long-
term clinical data are required to determine whether
the potential positive effects of incretin-based therapy
on b-cell health and the cardiovascular system are fully
realized.
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